Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitogen-activated protein kinase kinase kinase kinase 3 (MAP4K3), also known as Germinal Center-like Kinase (GLK), is a serine/threonine kinase that serves as a pivotal regulator in immune signaling and nutrient sensing (UniProt Q9Y6R4). It is a key upstream activator of the T-cell receptor (TCR) signaling pathway, where it phosphorylates PKC-theta to trigger NF-kappaB activation, and it also mediates amino acid-dependent activation of the mTORC1 pathway (Chuang et al., 2011; Yan et al., 2010). MAP4K3 mRNA and protein are frequently overexpressed in patients with systemic lupus erythematosus (SLE), where levels correlate with disease severity and serve as a diagnostic biomarker (Chuang et al., 2011). In oncology, MAP4K3 is implicated in the progression and metastasis of various cancers, including lung and pancreatic cancer, by promoting cell migration and survival (Hsu et al., 2016). Therapeutic strategies targeting MAP4K3 include the use of small molecule inhibitors to block its kinase activity and RNA interference (siRNA) to reduce its mRNA expression, aiming to treat autoimmune disorders and malignancies. Current research is exploring the potential of MAP4K3 as a therapeutic target to restore immune tolerance in autoimmune conditions and to inhibit tumor growth in resistant cancers (Chuang et al., 2019).
Reduction of MAP4K3 mRNA levels via RNA interference or inhibition of the MAP4K3 (GLK) kinase activity to suppress downstream PKC-theta/NF-kappaB and mTORC1 signaling pathways.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitogen-activated protein kinase kinase kinase kinase 3 (MAP4K3) (MAP4K3).